D. Boral Capital Reaffirms Buy Rating for Omeros (NASDAQ:OMER)

D. Boral Capital reiterated their buy rating on shares of Omeros (NASDAQ:OMER) in a research note issued to investors on Friday,Benzinga reports. They currently have a $36.00 price objective on the biopharmaceutical company’s stock.

A number of other brokerages have also commented on OMER. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Friday, January 17th. StockNews.com downgraded Omeros from a “hold” rating to a “sell” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Omeros presently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Price Performance

Shares of Omeros stock opened at $9.10 on Friday. Omeros has a one year low of $2.61 and a one year high of $13.60. The firm has a market capitalization of $527.35 million, a price-to-earnings ratio of -3.94 and a beta of 2.03. The business has a 50-day simple moving average of $8.70 and a 200 day simple moving average of $7.32.

Hedge Funds Weigh In On Omeros

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Two Sigma Investments LP boosted its stake in shares of Omeros by 8.8% in the 4th quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock worth $1,610,000 after buying an additional 13,201 shares during the last quarter. ProShare Advisors LLC boosted its stake in shares of Omeros by 75.0% in the 4th quarter. ProShare Advisors LLC now owns 18,496 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 7,927 shares during the last quarter. Nomura Holdings Inc. boosted its stake in shares of Omeros by 136.2% in the 4th quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock worth $7,383,000 after buying an additional 430,932 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Omeros by 46.2% in the 4th quarter. Millennium Management LLC now owns 85,671 shares of the biopharmaceutical company’s stock worth $846,000 after buying an additional 27,088 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Omeros by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 1,110 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.